Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Trends & Forecasts, Business Practice

The Battle for the Future of American Healthcare

Four years ago, The Medicine Maker made a bold prediction: regardless of who ended up in the White House, the pharma industry would have to weather change – with particular regard to drug pricing (1). Hillary Clinton had a long history of opposing rising drug prices, but Donald Trump was also making noises in favor of Medicare price negotiations and “repealing and replacing Obamacare”. In fact, one of Trump’s campaign promises was to allow American consumers to purchase drugs from abroad. Chris Dale, Director of Public Relations and Communications for Turchette, said that Medicare price negotiations and drug importation would become immediately politically untenable after a Clinton victory (due to the balance of power in the House of Representatives), and would only be possible if Trump won. Thus, we envisaged a strange situation whereby the USA would only see some of Clinton’s pharma-related policies if Trump became president. In the words of then Novartis CEO, Joe Jimenez, “We believe that, no matter which candidate wins, we will see a more difficult pricing environment in the US.” So did we?

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register